The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and AIFarm are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak
Strong
Over the last 90 days AIFarm has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, AIFarm is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
Begin Period Cash Flow
97.1 K
Free Cash Flow
-590.9 K
AIFarm
AIFarm Relative Risk vs. Return Landscape
If you would invest 0.30 in AIFarm on September 26, 2025 and sell it today you would earn a total of 0.00 from holding AIFarm or generate 0.0% return on investment over 90 days. AIFarm is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than AIFarm, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
AIFarm Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AIFarm's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as AIFarm, and traders can use it to determine the average amount a AIFarm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
Best Portfolio
Best Equity
Good Returns
Average Returns
Small Returns
Cash
Small Risk
Average Risk
High Risk
Huge Risk
AIFM
Based on monthly moving average AIFarm is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AIFarm by adding AIFarm to a well-diversified portfolio.
AIFarm Fundamentals Growth
AIFarm Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of AIFarm, and AIFarm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AIFarm Pink Sheet performance.
By examining AIFarm's fundamental ratios, stakeholders can obtain critical insights into AIFarm's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that AIFarm is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
AIFarm, Ltd., a development stage company, develops a proprietary growing system that designs and builds custom biodomes worldwide. AIFarm, Ltd. was founded in 2012 and is based in Kowloon, Hong Kong. Aifarm is traded on OTC Exchange in the United States.
Things to note about AIFarm performance evaluation
Checking the ongoing alerts about AIFarm for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for AIFarm help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
AIFarm generated a negative expected return over the last 90 days
AIFarm has some characteristics of a very speculative penny stock
AIFarm has a very high chance of going through financial distress in the upcoming years
AIFarm currently holds 54.73 K in liabilities. AIFarm has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist AIFarm until it has trouble settling it off, either with new capital or with free cash flow. So, AIFarm's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AIFarm sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AIFarm to invest in growth at high rates of return. When we think about AIFarm's use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (547.09 K) with profit before overhead, payroll, taxes, and interest of 0.
AIFarm currently holds about 88.27 K in cash with (590.9 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.13, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 51.0% of the company shares are held by company insiders
Evaluating AIFarm's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate AIFarm's pink sheet performance include:
Analyzing AIFarm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AIFarm's stock is overvalued or undervalued compared to its peers.
Examining AIFarm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating AIFarm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AIFarm's management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of AIFarm's pink sheet. These opinions can provide insight into AIFarm's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating AIFarm's pink sheet performance is not an exact science, and many factors can impact AIFarm's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Other Information on Investing in AIFarm Pink Sheet
AIFarm financial ratios help investors to determine whether AIFarm Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AIFarm with respect to the benefits of owning AIFarm security.